Klaus Veitinger

Klaus R.
Veitinger currently works at Promentis Pharmaceuticals, Inc., as Chairman, Neurogastrx, Inc., as Chairman from 2018, Sparrow Pharmaceuticals, Inc., as Chairman, and OrbiMed Advisors Private Equity, as Venture Partner from 2007.
Dr. Veitinger also formerly worked at Symbiomix Therapeutics LLC, as Director & Chief executive officer, Schwarz Pharma, Inc., as President & Chief Executive Officer from 1998 to 2006, Tricida, Inc., as Chairman from 2015 to 2023, Relypsa, Inc., as Vice Chairman from 2012 to 2015, Bone Care International, Inc., as Director, Biolex Therapeutics, Inc., as Director, Intercept Pharmaceuticals, Inc., as Independent Director from 2012 to 2016, Gelesis, Inc., as Director, Chroma Therapeutics Ltd., as Director from 2007 to 2012, Pharmaceutical Research & Manufacturers of America, as Director, scPharmaceuticals, Inc., as Independent Director from 2017 to 2025, and UCB Pharma GmbH, as Member-Management Board from 1990 to 2006.
Dr. Veitinger received his doctorate degree from Heidelberg University (Ohio) and Masters Business Admin degree from INSEAD.